Clinical trials of intensive versus less intensive control of hypertension: HOPE or HYPE?

Published

Journal Article

The recently published Heart Outcomes Prevention Evaluation trial (HOPE-3) demonstrated no benefit of lowering blood pressure with candesartan and hydrochlorothiazide in persons at intermediate cardiovascular risk and with adequate blood pressure control as determined by the enrolling physician. The results of Systolic Blood Pressure Intervention Trial (SPRINT) and HOPE-3 highlight the importance of considering differences in study design and patient population when interpreting the results of clinical trials.

Full Text

Duke Authors

Cited Authors

  • Wyatt, CM; Chertow, GM

Published Date

  • September 2016

Published In

Volume / Issue

  • 90 / 3

Start / End Page

  • 460 - 462

PubMed ID

  • 27521103

Pubmed Central ID

  • 27521103

Electronic International Standard Serial Number (EISSN)

  • 1523-1755

Digital Object Identifier (DOI)

  • 10.1016/j.kint.2016.06.021

Language

  • eng

Conference Location

  • United States